Press Releases
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Spear Bio for the Transformative Bio-Hermes-002 Study
Spear Bio joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias Washington D.C., Jan 12, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with Alamar Biosciences for the Transformative Bio-Hermes Studies
Washington D.C., Jan 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical […]
Clinical Neurology Specialists Partnering with Leading International Nonprofit to Accelerate Alzheimer’s Research in Las Vegas
Collaboration to Improve Access to Study for Alzheimer’s Disease Las Vegas, Nev. – Dec. 23 2025 – Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers […]
GAP Statement following the release of top-line updates from two Alzheimer’s clinical trials
The Global Alzheimer’s Platform Foundation® (GAP) today issued a statement following the release of top-line updates from two Alzheimer’s clinical trials: Recently, developments in two important Alzheimer’s clinical research studies were reported. The two studies were: Novo Nordisk’s Phase 3 EVOKE and EVOKE+ trials evaluating oral semaglutide, and Johnson & Johnson’s Phase 2b trial evaluating the […]
Sun Valley Research Center Joining Exceptional Research Site Network
International non-profit Global Alzheimer’s Platform Foundation expands research network in California to improve access to research opportunities Washington D.C., Oct. 14, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Sun Valley Research Center (SVRC) a private clinical research organization based in Imperial, California, to its global network of over 100 best-in-class research sites. SVRC […]
Why Partnerships are the Promising Pathway for Alzheimer’s Breakthroughs
Strategic collaborations are key to improving the pace and access to research. Undiagnosed and Overlooked Everyone knows someone impacted by Alzheimer’s disease, as it affects an estimated 55 million people worldwide. What is often overlooked is the shocking number of people who remain undiagnosed due to fear of going to a doctor, lack of access […]
Mission Viejo Takes Brain Health on the Road with Mobile Research Unit Ribbon Cutting
Mission Viejo, Aug 12, 2025— Brain health is being taken on the road in Mission Viejo with a Mobile Research Unit that will tour the West Coast to improve accessibility to brain health education and services. The Mobile Research Unit made its debut on August 9 with a ribbon cutting with The Healthy Brain Clinic […]
Tampa Takes Brain Health on the Road Debuting Mobile Research Unit
Florida Mobile Research Unit Launched with Axiom Brain Health at New Mt. Zion Baptist Church Tampa, FL Aug 6, 2025— Brain health is being taken on the road in Tampa as Axiom Brain Health launched a new Florida-based mobile research unit that will tour the state, to improve accessibility to brain health education and […]
Accelerating Alzheimer’s Research: Groundbreaking Alzheimer’s Disease Dataset Now Available to the Public
Data from Most Deeply Characterized Cohort Across Alzheimer’s Disease Released byGlobal Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative Washington D.C., July 31, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced today that data generated from the Bio-Hermes-001 study are now publicly available. This release […]
Global Alzheimer’s Platform Foundation and Genentech Collaborate to Expand Access to Alzheimer’s Research
Washington, DC -July 28, 2025 –The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research. This partnership will leverage the combined expertise of GAP’s Site Alliance […]